Pfizer Inc. (PFE) Release: New Study With CHANTIX®/CHAMPIX® (Varenicline) Tablets Suggests Favorable Benefit-Risk Profile in Adult Smokers With Major Depressive Disorder
10/16/2012 10:18:03 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a double-blind, placebo-controlled, randomized clinical trial designed to assess the efficacy and safety of CHANTIX®/CHAMPIX® (varenicline) 1 mg BID in comparison to placebo for smoking cessation in patients with a past or present diagnosis of Major Depressive Disorder (MDD). The study met its primary and secondary efficacy endpoints. Subjects in the varenicline group had a higher likelihood of quitting at week 12 (primary endpoint) and at week 52 (key secondary endpoint). In addition, psychiatric scales included for safety assessments did not show a difference between varenicline and placebo.
comments powered by